Genmab A/s (GMAB)

$29.11

+0.16

(+0.55%)

Market is closed - opens 8 PM, 23 Feb 2024

Insights on Genmab A/s

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 4.74B → 4.67B (in $), with an average decrease of 1.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 2.12B → 640.0M (in $), with an average decrease of 69.9% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 70.0% return, outperforming this stock by 93.8%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 232.5% return, outperforming this stock by 256.8%

Performance

  • $28.96
    $29.19
    $29.11
    downward going graph

    0.52%

    Downside

    Day's Volatility :0.79%

    Upside

    0.27%

    downward going graph
  • $26.32
    $43.00
    $29.11
    downward going graph

    9.58%

    Downside

    52 Weeks Volatility :38.79%

    Upside

    32.3%

    downward going graph

Returns

PeriodGenmab A/sSector (Health Care)Index (Russel 2000)
3 Months
-8.24%
11.5%
0.0%
6 Months
-21.61%
9.2%
0.0%
1 Year
-23.78%
12.0%
-6.6%
3 Years
-24.31%
27.4%
-21.4%

Highlights

Market Capitalization
19.2B
Book Value
$483.85
Earnings Per Share (EPS)
0.96
PE Ratio
30.16
PEG Ratio
1.13
Wall Street Target Price
40.41
Profit Margin
26.42%
Operating Margin TTM
35.7%
Return On Assets TTM
10.17%
Return On Equity TTM
14.78%
Revenue TTM
16.5B
Revenue Per Share TTM
25.22
Quarterly Revenue Growth YOY
-8.9%
Gross Profit TTM
14.6B
EBITDA
5.6B
Diluted Eps TTM
0.96
Quarterly Earnings Growth YOY
0.25
EPS Estimate Current Year
13.98
EPS Estimate Next Year
17.86
EPS Estimate Current Quarter
4.02
EPS Estimate Next Quarter
2.7

Analyst Recommendation

Buy
    48%Buy
    39%Hold
    12%Sell
Based on 33 Wall street analysts offering stock ratings for Genmab A/s(by analysts ranked 0 to 5 stars)
Based on 33 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
16
17
18
Hold
13
12
13
Sell
4
3
3

Analyst Forecast

What analysts predicted

Upside of 38.82%

Current $29.11
Target $40.41

Company Financials

FY18Y/Y Change
Revenue
463.5M
↑ 27.89%
Net Income
225.5M
↑ 33.4%
Net Profit Margin
48.66%
↑ 2.01%
FY19Y/Y Change
Revenue
804.5M
↑ 77.38%
Net Income
324.8M
↑ 47.13%
Net Profit Margin
40.37%
↓ 8.29%
FY20Y/Y Change
Revenue
1.7B
↑ 88.43%
Net Income
786.5M
↑ 119.67%
Net Profit Margin
47.06%
↑ 6.69%
FY21Y/Y Change
Revenue
1.3B
↓ 16.11%
Net Income
458.0M
↓ 36.78%
Net Profit Margin
35.46%
↓ 11.6%
FY22Y/Y Change
Revenue
2.1B
↑ 72.07%
Net Income
794.8M
↑ 83.58%
Net Profit Margin
37.83%
↑ 2.37%
FY23Y/Y Change
Revenue
16.5B
↑ 12.87%
Net Income
4.4B
↓ 21.19%
Net Profit Margin
26.42%
↓ 11.41%
Q3 FY22Q/Q Change
Revenue
540.2M
↑ 29.25%
Net Income
341.3M
↑ 36.54%
Net Profit Margin
63.18%
↑ 3.38%
Q4 FY22Q/Q Change
Revenue
752.4M
↑ 27.89%
Net Income
84.1M
↓ 77.38%
Net Profit Margin
11.17%
↓ 52.01%
Q1 FY23Q/Q Change
Revenue
417.8M
↓ 45.4%
Net Income
33.1M
↓ 61.3%
Net Profit Margin
7.92%
↓ 3.25%
Q2 FY23Q/Q Change
Revenue
615.3M
↑ 47.09%
Net Income
198.9M
↑ 500.44%
Net Profit Margin
32.32%
↑ 24.4%
Q3 FY23Q/Q Change
Revenue
4.7B
↑ 13.01%
Net Income
2.1B
↑ 56.89%
Net Profit Margin
44.88%
↑ 12.56%
Q4 FY23Q/Q Change
Revenue
4.7B
↓ 1.39%
Net Income
640.0M
↓ 69.94%
Net Profit Margin
13.68%
↓ 31.2%
FY18Y/Y Change
Total Assets
1.3B
↑ 28.14%
Total Liabilities
68.4M
↑ 35.04%
FY19Y/Y Change
Total Assets
2.3B
↑ 78.99%
Total Liabilities
164.3M
↑ 145.39%
FY20Y/Y Change
Total Assets
3.5B
↑ 39.61%
Total Liabilities
334.2M
↑ 84.49%
FY21Y/Y Change
Total Assets
3.7B
↑ 16.48%
Total Liabilities
370.1M
↑ 20.23%
FY22Y/Y Change
Total Assets
4.4B
↑ 22.95%
Total Liabilities
408.4M
↑ 16.7%
FY23Y/Y Change
Total Assets
35.3B
↑ 16.55%
Total Liabilities
3.7B
↑ 29.68%
Q3 FY22Q/Q Change
Total Assets
4.1B
↑ 11.68%
Total Liabilities
532.6M
↑ 34.57%
Q4 FY22Q/Q Change
Total Assets
4.4B
↓ 1.33%
Total Liabilities
408.4M
↓ 29.59%
Q1 FY23Q/Q Change
Total Assets
4.4B
↑ 0.38%
Total Liabilities
469.1M
↑ 12.94%
Q2 FY23Q/Q Change
Total Assets
4.7B
↑ 5.21%
Total Liabilities
472.4M
↑ 0.59%
Q3 FY23Q/Q Change
Total Assets
35.2B
↑ 10.19%
Total Liabilities
4.1B
↑ 28.02%
Q4 FY23Q/Q Change
Total Assets
35.3B
↑ 0.14%
Total Liabilities
3.7B
↓ 10.83%
FY18Y/Y Change
Operating Cash Flow
155.5M
↓ 36.14%
Investing Cash Flow
-272.4M
↑ 166.34%
Financing Cash Flow
-10.9M
↓ 132.99%
FY19Y/Y Change
Operating Cash Flow
198.8M
↑ 30.67%
Investing Cash Flow
-297.3M
↑ 11.53%
Financing Cash Flow
548.8M
↓ 5262.13%
FY20Y/Y Change
Operating Cash Flow
1.1B
↑ 385.14%
Investing Cash Flow
-388.6M
↑ 18.56%
Financing Cash Flow
11.7M
↓ 98.06%
FY21Y/Y Change
Operating Cash Flow
339.2M
↓ 65.37%
Investing Cash Flow
-146.3M
↓ 59.12%
Financing Cash Flow
-63.9M
↓ 691.55%
FY22Y/Y Change
Operating Cash Flow
563.1M
↑ 75.58%
Investing Cash Flow
-397.4M
↑ 187.3%
Financing Cash Flow
-113.6M
↑ 87.86%
Q3 FY22Q/Q Change
Operating Cash Flow
260.1M
↑ 105.21%
Investing Cash Flow
-182.7M
↑ 139.93%
Financing Cash Flow
-84.9M
↑ 200.0%
Q4 FY22Q/Q Change
Operating Cash Flow
57.3M
↓ 79.78%
Investing Cash Flow
-19.6M
↓ 90.16%
Financing Cash Flow
18.9M
↓ 120.4%
Q1 FY23Q/Q Change
Operating Cash Flow
473.6M
↑ 712.81%
Investing Cash Flow
-268.7M
↑ 1249.26%
Financing Cash Flow
-89.5M
↓ 566.41%
Q2 FY23Q/Q Change
Operating Cash Flow
63.9M
↓ 86.52%
Investing Cash Flow
-269.0M
↑ 0.0%
Financing Cash Flow
1.0M
↓ 101.15%
Q3 FY23Q/Q Change
Operating Cash Flow
2.0B
↑ 367.2%
Investing Cash Flow
1.0B
↓ 154.93%
Financing Cash Flow
20.0M
↑ 185.71%

Technicals Summary

Sell

Neutral

Buy

Genmab A/s is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Genmab A/s
Genmab A/s
0.94%
-21.61%
-23.78%
-24.31%
59.24%
Moderna, Inc.
Moderna, Inc.
-12.15%
-24.65%
-44.62%
-45.04%
340.59%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
1.06%
13.35%
27.37%
106.88%
125.51%
Novo Nordisk A/s
Novo Nordisk A/s
14.64%
30.73%
70.02%
232.45%
385.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.65%
19.76%
42.56%
95.21%
125.9%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Genmab A/s
Genmab A/s
30.16
30.16
1.13
13.98
0.15
0.1
NA
483.85
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-12.5
-0.22
-0.07
NA
35.32
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
27.43
27.43
1.93
44.85
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
44.55
44.55
4.4
3.29
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
30.28
30.28
0.57
16.74
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Genmab A/s
Genmab A/s
Buy
$19.2B
59.24%
30.16
26.42%
Moderna, Inc.
Moderna, Inc.
Buy
$33.7B
340.59%
24.73
-38.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$104.7B
125.51%
27.43
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$548.5B
385.86%
44.55
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$108.7B
125.9%
30.28
36.68%

Institutional Holdings

  • AllianceBernstein L.P.

    1.46%
  • BlackRock Inc

    0.74%
  • Capital Research & Mgmt Co - Division 3

    0.66%
  • Macquarie Group Ltd

    0.50%
  • Harding Loevner L.P.

    0.49%
  • Wellington Management Company LLP

    0.37%

Company Information

Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund.

Organization
Genmab A/s
Employees
2204
CEO
Dr. Jan G.J. van de Winkel Ph.D.
Industry
Health Technology

FAQs